PTC Therapeutics gets FDA Complete Response Letter

PTC Therapeutics, Inc. reported that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for vatiquinone.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

PTC Therapeutics, Inc. reported that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for vatiquinone. This application sought approval of vatiquinone to treat children and adults living with Friedreich’s ataxia, a rare neurodegenerative disease. The company disclosed this development through a press release furnished as an exhibit to this current report.

The Complete Response Letter means the FDA has completed its review of the application but did not approve vatiquinone in its current form, and additional steps would be required before any potential approval. No financial results or updated guidance are discussed in this report.

Positive

None.

Negative

FDA issues Complete Response Letter for vatiquinone NDA, meaning vatiquinone is not approved in its current form for Friedreich’s ataxia and cannot be marketed for this indication based on this submission.

Insights

FDA Complete Response Letter is a clear regulatory setback for vatiquinone.

PTC Therapeutics, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application for vatiquinone in Friedreich’s ataxia. A Complete Response Letter indicates the FDA review is finished but the application is not approved in its current form, so vatiquinone cannot be marketed for this use based on this submission.

This outcome is significant because vatiquinone was being developed to treat both children and adults living with Friedreich’s ataxia, a serious rare disease with limited treatment options. The letter typically implies the need for additional information, analyses, or studies, although the specific requirements are not described in this report.

Future regulatory or development steps for vatiquinone will depend on the content of the Complete Response Letter and the company’s response, which are not detailed here. Subsequent company disclosures may clarify the path forward for this program and any associated timelines or costs.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PTC Therapeutics (PTCT) disclose in this Form 8-K?

PTC Therapeutics disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for vatiquinone for Friedreich’s ataxia.

What is vatiquinone being developed for at PTC Therapeutics (PTCT)?

Vatiquinone is being developed by PTC Therapeutics for the treatment of children and adults living with Friedreich’s ataxia, a rare neurodegenerative disease.

What does a Complete Response Letter from the FDA mean for PTCT?

A Complete Response Letter means the FDA has completed review of the New Drug Application but did not approve vatiquinone in its current form, so it cannot be marketed for this use based on this submission.

Does this PTCT filing include financial results or earnings data?

No. The report focuses on the FDA’s Complete Response Letter for vatiquinone and does not present financial results or earnings data.

How did PTC Therapeutics communicate the FDA decision on vatiquinone?

PTC Therapeutics communicated the FDA decision through a press release dated August 19, 2025, which is furnished as Exhibit 99.1 and incorporated by reference into this report.

Is the vatiquinone press release considered filed information for PTCT?

The company states that the information in Item 7.01 and Exhibit 99.1 is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/19/2025 - 08:10 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)


Delaware	001-35969	04-3416587
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)


500 Warren Corporate Center Drive
Warren, NJ			07059
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s telephone number, including area code: (908) 222-7000

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	PTCT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 19, 2025, PTC Therapeutics, Inc. issued a press release announcing that it had received a Complete Response Letter from the U.S. Food and Drug Administration related to the New Drug Application for vatiquinone for the treatment of children and adults living with Friedreich’s ataxia. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference into this Item 7.01.

The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
99.1		Press Release, dated August 19, 2025 issued by PTC Therapeutics, Inc.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


	PTC Therapeutics, Inc.

Date: August 19, 2025	By:	/s/ Pierre Gravier
	Name:	Pierre Gravier
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

PTC Therapeutics gets FDA Complete Response Letter